$RLBD interview highlights several of key strategi
Post# of 17844
(Total Views: 172)
Posted On: 06/15/2021 1:45:51 PM
$RLBD interview highlights several of key strategic relationships like the resulting affiliation with Turning Point Brands, Inc. (NYSE: TPB), the retention of renowned chemist Dr. Adel Rammal, PhD as Chief Scientific Officer and their multiple existing CBD brands including CBD Pharmacy®, Omega Hemp®, and Humboldt®.
“We started the Company in 2017 with a proprietary technology that is unique to our Company. We attracted a strategic investor, Turning Point Brands, Inc. (NYSE: TPB), a billion-dollar New York Stock Exchange Company, they own a little over 23% of the Company. After the passing of the Farm Bill, I saw that the commoditization of cannabinoids (CBD) was inevitable, prices would start to collapse, making branded and formulated products the longer-term marketplace to put the Company in,” explains Kidrin. “Today we stand at an inflection point for the Company as we are ideally positioned for scale and growth. We are thankful for the opportunity to share our story with our shareholders and the SmallCapVoice.com listening audience.”
“We started the Company in 2017 with a proprietary technology that is unique to our Company. We attracted a strategic investor, Turning Point Brands, Inc. (NYSE: TPB), a billion-dollar New York Stock Exchange Company, they own a little over 23% of the Company. After the passing of the Farm Bill, I saw that the commoditization of cannabinoids (CBD) was inevitable, prices would start to collapse, making branded and formulated products the longer-term marketplace to put the Company in,” explains Kidrin. “Today we stand at an inflection point for the Company as we are ideally positioned for scale and growth. We are thankful for the opportunity to share our story with our shareholders and the SmallCapVoice.com listening audience.”
(0)
(0)Scroll down for more posts ▼